CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age? Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial

Clinical Trial2014 Jan 21;129(3):304-12.

JOURNAL:Circulation. Article Link

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.

Lee CW, Ahn JM, Park SJ et al. Keywords: dAPT duration; coronary artery disease; DES; platelet aggregation; inhibitors; stents; thrombosis

FULL TEXT PDF